Drawing for BELLA

USPTO serial 90639165

BELLA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CHOSID, ROBIN S
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BELLA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kimberly S. Grimsley

Kimberly S. Grimsley OLIVER & GRIMSLEY, LLC1 OLYMPIC PLACESUITE 900TOWSON, MD 21204

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic kits comprised of medical diagnostic assays for use in disease detection, screening, treating and monitoring, namely, monitoring COVID-19 and other infectious diseases; Respiratory rapid tests, namely, medical diagnostic assays for use in performing respiratory rapid tests related to COVID-19 and other infectious diseases; Medical diagnostic kits comprised of reagents and assays for use in disease detection, screening, treating and monitoring, including, monitoring COVID-19 and other infectious diseases and also including swabs, including nasal and throat swabs, and medical sample tubes; COVID-19 rapid tests comprising medical diagnostic reagents and assays for withdrawing and testing respiratory droplets and also including parts and fittings thereofACTIVE—
009Downloadable computer application software for mobile phones, namely, software for covid-19 and other infectious disease identification; Downloadable computer application software for computers, namely, software for covid-19 and other infectious disease identification; Downloadable mobile applications for health screenings relating to COVID-19 and other infectious disease; Downloadable mobile applications for tracking and reporting health conditions and symptoms; Scientific apparatus and instruments, namely, COVID-19 rapid tests for withdrawing and testing respiratory droplets for clinical, medical, research, and scientific purposes and parts and fittings thereof; Material testing apparatus and instruments, for identifying and testing pathogens and biomarkers in respiratory droplets for clinical, medical, research, and scientific purposes related to COVID-19 and other infectious diseases; Apparatus for transmission of communication; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical, medical, research, and scientific purposes, namely, for COVID-19 and other infectious diseasesACTIVE—
010Medical instruments, namely, biosensors for detecting Covid-19 and other infectious diseases in a patient; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for medical diagnostic purposes, namely, for COVID-19 and other infectious diseaseACTIVE—
042Providing temporary use of online non-downloadable software for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; Providing temporary use of online non-downloadable software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Providing temporary use of web-based software applications for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Software as a service (SAAS) services featuring software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Electronic storage of information concerning persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departments, and information concerning physical sites visited by persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departmentsACTIVE—
044Healthcare services, namely, treatment of patients for infectious diseases or medical disorders; Medical and healthcare information, consultancy and advisory services relating to infections, viruses, SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Providing a web site featuring medical information; Health care services, namely, disease management programs; Telehealth services, namely, providing telemedicine and services in conjunction with providing medical and healthcare services; Mobile healthcare services in the field of Covid-19 and other infectious disease testing, health assessments, intravenous infusion therapy, facilitating appointments; Medical screening services in the field of Covid-19 and other infectious diseases in a patient; Polymerase chain reaction (PCR) testing, rapid body antigen testing, and nucleic acid amplification testing for identifying and testing pathogens and biomarkers in respiratory droplets for medical diagnostic purposes related to COVID-19 and other infectious diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 29, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 29, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 6, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 5, 2023EX1GSOU EXTENSION 1 GRANTED—
Jul 3, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 27, 2023EXT1SOU EXTENSION 1 FILED—
Jun 27, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 19, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 19, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 19, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 27, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 1, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 1, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 12, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 29, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 21, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Sep 21, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 21, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 21, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 1, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 31, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 31, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 8, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 8, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 8, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 1, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 30, 2021DOCKASSIGNED TO EXAMINER—
Jul 19, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 15, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance